Reduced soluble Toll-like receptors 2 in type 2 diabetes.
Soluble forms of Toll-like receptors (sTLR) 2 and 4 exert negative regulatory control on membrane-bound receptor activation. The study estimates the sTLR2 and sTLR4's serum levels in type 2 diabetes (T2D) and evaluates their relationship with metabolic and inflammatory parameters. Sixty three patients with T2D and 25 controls were enrolled. sTLR were assayed through ELISA. Inflammatory markers included Interleukin 6 (IL-6), high sensitivity C-reactive protein (hs-CRP) and tumour necrosis factor α. Analysis demonstrated lower sTLR2 level in T2D than in control subjects (1.15 ± 0.65 versus 1.44 ± 0.60 ng/ml, p = .019) while sTLR4 level remained similar (0.09 ± 0.16 versus 0.07 ± 0.12 ng/ml, p > .05) despite higher IL-6 (2.65 ± 2.46 versus 1.44 ± 0.22 pg/ml, p = .005) and hs-CRP (2.79 ± 2.89 versus 0.70 ± 0.89 mg/l, p < .001) concentrations. Neither sTLR correlated with BMI, HbA1c, plasma glucose and analysed cytokines (p > .05). The sTLR2 serum level in T2D patients was reduced despite elevated inflammatory parameters.